Vanguard Group Inc Longeveron Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.25 - $2.51 $9,712 - $19,502	7,770 Added 4.24%	190,975 $259,000
Q3 2023 Nov 14, 2023	SELL	$2.15 - $3.59 $2,453 - $4,096	-1,141 Reduced 0.62%	183,205 $428,000
Q4 2022 Feb 10, 2023	BUY	$2.81 - $39.7 $221 - $3,136	79 Added 0.04%	184,346 $593,000
Q3 2022 Nov 14, 2022	BUY	$3.97 - $42.7 $42,082 - $452,620	10,600 Added 6.1%	184,267 $682,000
Q2 2022 Aug 12, 2022	BUY	$5.93 - $15.61 $342,765 - $902,289	57,802 Added 49.89%	173,667 $1.03 Million
Q1 2022 May 13, 2022	BUY	$5.06 - $13.8 $87,178 - $237,760	17,229 Added 17.47%	115,865 $1.6 Million
Q4 2021 Feb 14, 2022	SELL	$2.92 - $42.3 $99,230 - $1.44 Million	-33,983 Reduced 25.62%	98,636 $1.19 Million
Q3 2021 Nov 12, 2021	BUY	$3.4 - $8.3 $4,620 - $11,279	1,359 Added 1.04%	132,619 $468,000
Q2 2021 Aug 13, 2021	BUY	$5.2 - $8.13 $682,552 - $1.07 Million	131,260 New	131,260 $1.07 Million

581

Ticker LGVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,925,940
Market Cap $12.4M
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.